Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective.
Advances in our understanding of rheumatoid synovitis have been coupled with increasingly refined methods from biotechnology to produce promising therapeutic agents. Monoclonal antibodies (MoAbs), recombinant cytokines, cytokine receptor fusion proteins and other biologics have been elevated from the status of novel reagents applied in phase I toxicity trials to, in some cases, substantially evaluated and validated tools awaiting federal regulatory approval. Biologic agents will soon be released for the treatment of patients with RA. We review some of the most promising preclinical work that supports a position of optimism regarding the future of RA. We also speculate on the potential role for biologics in future management of patients with RA.
Wallis
W J
WJ
Virginia Mason Medical Center, Seattle, Washington, USA.
Furst
D E
DE
Strand
V
V
Keystone
E
E
D001172:Arthritis, Rheumatoid / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use; D000068800:Etanercept; D005544:Forecasting; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000639:trends*; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology / Q000627:therapeutic use
D016207:Cytokines; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept